Leiden, 3 December 2020 – KU Leuven, a leading research institution and one of the top 50 universities in the world and Batavia Biosciences, a contract development and manufacturing organization focused on delivering sustainable manufacturing solutions in the field of vaccines and oncology, today announce their partnership on the development of a vector based COVID-19…
In an article with the title “New Polio Vaccine Becomes The First Vaccine Under the WHO’s Emergency Use Listing”, The Science Times stated that that Batavia Biosciences developed the nOPV2 vaccine that has now been approved for emergency use by the WHO. This statement is, in fact, incorrect, the nOPV2 vaccine approved for emergency use…
Saint-Herblain, France, and Leiden, Netherlands, June 15, 2020 – Batavia Biosciences (“Batavia”) and Valneva Sweden AB, the Swedish subsidiary of Valneva SE (“Valneva”) today announced that they have entered into a collaboration agreement to accelerate market-access of a low-cost inactivated polio vaccine (IPV). This work is supported under GPEI.[1] In 2019, Batavia received a grant…
As the COVID-19 pandemic continues, we would like to update you on our business status. As a company at the forefront of epidemic preparedness, staying operational is critical as it means we can continue the valuable work we do with our clients and partners to develop treatments and cures for vaccine preventable diseases. We put…
The Bill & Melinda Gates Foundation supports international collaboration to expand global access to life-saving vaccines PHILADELPHIA — (April 29, 2020) — The Wistar Institute and Batavia Biosciences announce the launch of a strategic collaboration aimed to streamline the clinical grade manufacture and global distribution of Wistar’s rubella vaccine seed stock commonly known as RA…
Leiden, April 15, 2020 – Immutep and Batavia Biosciences announce today that they have successfully generated a high yielding cell line for an IgG4-based antibody for LAG-3 immunotherapy for autoimmune diseases, known as IMP761, reaching an important milestone in the preclinical development of the compound. This achievement triggers a green light to move forward with…
Mutual expertise drives innovations to address supply issues for vaccines for outbreak pathogens NEW YORK — MARCH 5, 2020 — IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, and Batavia Biosciences, a contract development and manufacturing organization focused on delivering sustainable manufacturing solutions in the field of infectious disease…
Ten years ago, Christopher Yallop and Menzo Havenga incorporated Batavia Biosciences at the chamber of commerce in the Netherlands. The company started operations on January 1, 2010 at that time with 7 employees (our “magnificent seven”). Today, we are a 100 people strong with operations in the US, Asia, and the Netherlands and we are…
We are proud to announce that our CEO, Menzo Havenga, has won the CEO Today Healthcare Award 2019. Menzo is praised for his leading role in the biopharmaceutical medicines development sector and his strive to ensure biopharmaceuticals are affordable and available for all in need. In an interview with CEO Today Magazine, Menzo Havenga commented:…
Leiden, the Netherlands, Nov 12, 2019 – We are proud to announce that we have partnered with IAVI under an award they have received from the US Defense Threat Reduction Agency (DTRA) to develop a VSV-based vaccine against Marburg virus. (Link to IAVI press release) This is the second collaboration between Batavia and IAVI on VSV…